# Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT00030446** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 50 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00030446
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01-10
- **Primary completion:** 2005-02-11
- **Final completion:** 2009-12-21
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030446, "Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00030446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*